

Date and Time:	18th December 2012; 10.30 – 16.30hrs
-----------------------	--

Minutes:		
Guideline Development Group Meeting		
Place:	<i>NCGC Boardroom, Great Portland Street, London</i>	
Present:	<p>Philip Conaghan (Chair) [arrived at 12.10pm] Mark Porcheret (MP) Ian Bernstein (IB) Fraser Birrell (FB) [Chaired until 12.10pm] Michael Doherty (MD) Peter Kay (PK) Rob Middleton (RM) Brian Lucas (BL) Krysia Dziedzic (KD) Weiya Zhang (WZ) Richard Frearson (RF) Tony Whiting (TW) Jo Cumming (JC) Erika Baker (EB) Elspeth Wise (EW) (via TC)</p> <p>Vanessa Delgado Nunes, Guideline Lead and Senior Research Fellow (VDN) Emmert Roberts, Research Fellow (ER) Sara Buckner, Research Fellow (SB) Margaret Constanti, Health Economist (MC) Sue Latchem, Guideline Lead and Operations Director (SL) Paul Miller, Information Scientist (PM)</p> <p>Clifford Middleton, Guidelines Commissioning Manager, NICE (only pm)</p>	
Co-opted experts		
Jill Halstead Rastrick Kirsty Bancroft		
Apologies:		
Richard Frearson Brian Lucas Ben Doak		
Observers:		
None for this meeting		

Declarations of Interest

IB

Declared Personal pecuniary non-specific interests

- IB lectured at the King's Fund on Tuesday 27th November on developing an integrated care model for musculoskeletal services in NHS NW London. The meeting was sponsored by Pfizer. IB received dinner and has been promised an honorarium of £250. The reps were not present during the meeting and IB did not meet with them before or after the meeting.
- IB attended a lecture at ARMA on Wednesday 21st November and was invited to dinner to meet Martin McShane, Director of Domain 2 (Long Term Conditions) at the NHS Commissioning Board. The lecture and dinner were sponsored by Roche.
- IB attended a clinical meeting at Gordon House Surgery on Wednesday 14th November. The meeting was sponsored by Pfizer, who were promoting Viagra. No musculoskeletal drugs were discussed. Sandwiches were provided. No attendees received any money, gifts or professional samples from Pfizer. Personal pecuniary non-specific .
- IB attended a clinical network meeting at ARMA on Thursday 22nd November as a national clinical advisor and did not receive any payment. IB declared his interest with ARMA at the initial declaration.

WZ

Declared a personal pecuniary non-specific interests

- WZ was invited by Asia Pacific League of Association for Rheumatology (APLAR) to give a talk on Evidence based diagnosis and management of osteoarthritis in Shanghai on 19th Jan 2013. Travel and hotel will be paid.

EW

Declared personal non-pecuniary non-specific interests

- EW attended a day course on dermatology run by Astellas and is not aware of Astellas making any products related to OA.
- EW attended the Primary Care Rheumatology Society Annual Meeting - self funded.

Declared Personal pecuniary non-specific interests

- EW attended the American College of Rheumatology Meeting sponsored by the Primary Care Rheumatology Society.
- EW presented at a BMJ Musculoskeletal Masterclass in Abu Dhabi - funded by BMJ publishing.

MD

Declared a personal pecuniary specific interest

- December 12th – MD attended a whole day ad hoc advisory board for Neusentis (Pfizer) in Cambridge, UK to discuss the study designs to test a new urate lowering agent. His travel expenses (car – no accommodation required) were covered and he will receive a personal honorarium (£2000) in due course.

Declared a personal pecuniary non-specific interests

- December 10th – MD attended the French Rheumatology Association meeting in Paris to talk on Gout (Patient and Health Care Provider Barriers to Care). The cost of his expenses (return train, 1 night's accommodation) were covered by the meeting.
- 16th/17th December – MD will attend a meeting in Florence to finalise a multi-author review on risks related to high and low uric acid levels. Menarini (Italy) will pay for the travel and 1 night's accommodation/subsistence (no honorarium involved).

There were no changes in any of the other GDG members' or NCGC staff's DOIs since the last meeting.

MD will be asked to withdraw from discussions where Celebrex (Pfizer) will be listed as a comparator. No further actions were taken following these declarations and none of the GDG members withdrew as none of the declarations conflicted with clinical areas to be discussed during the GDG meeting

1. Fraser Birrell (acting chair until 12.10pm) welcomed the group to the sixth meeting of this GDG. FB asked the GDG for any new DOIs since GDG meeting 1.
2. Sara Buckner presented the evidence related to the clinical and cost effectiveness of decision aids in the management of OA.
3. Fraser Birrell, Vanessa Delgado Nunes and Sue Latchem facilitated discussion and decision making with the GDG in terms of the evidence for the clinical and cost effectiveness of decision aids in the management of OA.
4. Kirsty Bancroft, co-opted expert to the OA GDG (occupational therapy) delivered a presentation on the role of OT in OA.
5. Emmert Roberts presented the clinical and cost effectiveness evidence related to the reinforcement of core treatments as part of the patient review/follow-up in the management of OA.
6. Philip Conaghan arrived at 12.10pm and resumed chairing.
7. Jill Halstead-Rastrick, co-opted expert to the OA GDG (podiatry) delivered a presentation on the role of podiatry in OA.
8. Philip Conaghan, Vanessa Delgado Nunes and Sue Latchem facilitated discussion and decision making with the GDG in terms of the evidence for reinforcing core treatments as part of the patient review/follow-up in the management of OA.
9. Margaret Constanti delivered an update to the GDG on progress in the modelling work
10. Lyn Knott delivered a presentation on the role of the NICE medical editor in supporting the GDG finalise recommendations.
11. Vanessa Delgado Nunes brought to the attention to the GDG the recent MHRA alert on NSAIDs cardiovascular risk.
12. Vanessa Delgado Nunes presented to the GDG the evidence review protocol on the time to referral to surgery for people with OA. It was decided that this protocol would be revisited at the January 2013 meeting.
13. Philip Conaghan asked the GDG whether there were any items under AOB and closed the meeting at 16.45hrs.

Date, time and venue of the next meeting

18th December 2012, 10:30 – 16:30hrs.

